Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with EGFR-TKI for EGFR-mutant advanced non-squamous non-small cell lung cancer
ChiCTR1800020397Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jan 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: progression-free survival. Started Jan 2019; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800020397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020397.